Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients

Epilepsia

Volumn 44, Issue 7, 2003, Pages 917-922

  Doose, Dennis R ^a   Brodie, Martin J ^b   Wilson, Elaine A ^b   Chadwick, David ^c   Oxbury, John ^d   Berry, David J ^e   Schwabe, Stefan ^a   Bialer, Meir ^f  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b WESTERN INFIRMARY   (United Kingdom)

^c Clinical Trials Unit   (Australia)

^d RADCLIFFE INFIRMARY   (United Kingdom)

^e Medical Toxicology Unit   (United Kingdom)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antiepileptic; Drug interactions; Drugs (AEDs); Epilepsy; Lamotrigine; Topiramate

Indexed keywords

LAMOTRIGINE; TOPIRAMATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; EPILEPSY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; TRIAZINES;

EID: 0037816146     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2003.64402.x     Document Type: Article

References (22)

1. Maryanoff BE, Nortey SO, Gardocki JF, et al. Anticonvulsant O-alkyl sulfamates: 2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate and related compounds. J Med Chem 1987;30:880-7.
2. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:450-60.
3. Ben-Menachem E. Topiramate. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs, 4th ed. New York: Raven Press, 1995:1063-70.
4. Doose DR, Streeter AJ. Topiramate: chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS. et al., eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:727-34.
5. Gidal BE. Topiramate: drug interactions. In: Levy RH, Mattson TH, Meldrum BS, et al., eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:735-9.
6. Doose DR, Walker SA, Gisclon LG, et al. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate: a novel antiepileptic drug. J Clin Pharmacol 1996;36:884-91.
7. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000;40(suppl 1):S61-5.
8. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:774-80.
9. Sachdeo RC, Sachdeo SK, Levy RH, et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 2002;43:691-6.
10. Wu WN, McKown LA. Recent advances in biotransformation of CNS and cardiovascular agents. Curr Drug Metab 2000;1:255-70.
11. Stephens LJ, Sill GJ, Brodie MJ. Lamotrigine and topiramate may be a useful combination. Lancet 1998;351:958-9.
12. Bialer M, Walker MC, Sander JW. Pros and cons for the development of new antiepileptic drugs. CNS Drugs 2002;16:285-9.
13. Riffitts JM, Gisclon LG, Stubb TJ, et al. A capillary gas chromatographic assay with nitrogen phosphorous detection for the quantification of topiramate in human plasma, urine and whole blood. J Pharm Biomed Anal 1999;19:363-71.
14. Schuirman DJ, A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioequivalence. J Pharmacokinet Biopharm 1987;15:657-80.
15. Rosenfeld WE, Doose DR, Walker SA, et al. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997;38:317-22.
16. Doose DR, Wang S-S, Padmanabhan M, et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and non-obese female subjects. Epilepsia 2003;44:540-9.
17. Dickins M, Chen C. Lamotrigine: chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:370-9.
18. Radominska-Pandya A, Czernik PJ, Little JM. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999;31:817-99.
19. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferase metabolism, expression and disease. Annu Rev Pharmacol 2000;40:581-616.
20. Wnuk W, Volanski A, Foletti G. Topiramate decreases lamotrigine concentrations. Ther Drug Monit 1999;21:449-59.
21. May TW, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age and comedication. Ther Drug Monit 2002;24:366-74.
22. Berry DJ, Besag FM, Pool F, et al. Lack of an effect of topiramate on lamotrigine serum concentration. Epilepsia 2002;43:818-23.